Drug Trial Radar · NCT06188325
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
Last checked: Nov 20, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jan 1, 2018
Primary completion
Mar 26, 2018
Study completion Mar 26, 2018
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate dose proportionality and pharmacokinetics for three different dose levels of eliglustat after single and repeated administration.
Conditions
- Gaucher's Disease
Interventions
EliglustatDrug
Pharmaceutical form:Capsule-Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) parameter: CmaxTime frame: Multiple timepoints up to Day 35
- Pharmacokinetic (PK) parameter: tmaxTime frame: Multiple timepoints up to Day 35
- Pharmacokinetic (PK) parameter: AUC0-TTime frame: Multiple timepoints up to Day 35
- Pharmacokinetic (PK) parameter: AUCTime frame: Multiple timepoints up to Day 35
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M.D.Covance Clinical Research Unit 1341 W
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.